2016年美国13-17岁青少年国家、地区、州及部分地方区域疫苗接种覆盖率
美国CDC分析2016年国家青少年免疫调查中20,475名13-17岁青少年的数据,估算疫苗接种覆盖率。2015-2016年间,≥1剂Tdap覆盖率从86.4%升至88.0%,≥1剂HPV疫苗覆盖率从56.1%升至60.4%;17岁青少年≥2剂MenACWY覆盖率从33.3%升至39.1%。2016年43.4%青少年按更新HPV建议完成HPV疫苗系列接种。
要点
- 2015-2016年≥1剂Tdap覆盖率从86.4%升至88.0%,≥1剂HPV疫苗从56.1%升至60.4%。
- 17岁青少年≥2剂MenACWY覆盖率从33.3%升至39.1%。
- 2016年43.4%青少年完成HPV疫苗系列接种(女性49.5%,男性37.5%)。
核心结论
- 青少年疫苗接种覆盖率总体持续改善,但增加HPV相关癌症预防方面仍存在大量机会。
研究设计与样本
- CDC分析2016年国家青少年免疫调查(NIS-Teen)中20,475名13-17岁青少年的数据,估算美国青少年疫苗接种覆盖率。
主要发现
- 2015-2016年,≥1剂Tdap覆盖率从86.4%升至88.0%,≥1剂HPV疫苗覆盖率从56.1%升至60.4%。
- 17岁青少年≥2剂MenACWY覆盖率从33.3%升至39.1%。
- 2016年,43.4%青少年(女性49.5%,男性37.5%)按更新HPV建议回顾性应用后完成HPV疫苗系列接种。
- ≥1剂HPV疫苗覆盖率按大都市统计区(MSA)状态不同,非MSA地区最低(50.4%),MSA中心城区最高(65.9%)。
关键数值与推荐
- ACIP建议青少年在11-12岁常规接种Tdap、MenACWY和HPV疫苗。
- ACIP建议对未按时完成儿童期疫苗接种的青少年补种乙型肝炎疫苗、MMR疫苗和水痘疫苗。
- ACIP建议在16岁接种一剂MenACWY加强针。
- 2016年12月,ACIP更新HPV疫苗建议,纳入免疫功能正常青少年在15岁生日前启动接种系列的2剂程序。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Advisory Committee on Immunization Practices (ACIP) recommends that adolescents routinely receive tetanus, diphtheria, and acellular pertussis vaccine (Tdap), meningococcal conjugate vaccine (MenACWY), and human papillomavirus (HPV) vaccine (1) at age 11-12 years. ACIP also recommends catch-up vaccination with hepatitis B vaccine, measles, mumps, and rubella (MMR) vaccine, and varicella vaccine for adolescents who are not up to date with childhood vaccinations. ACIP recommends a booster dose of MenACWY at age 16 years (1). In December 2016, ACIP updated HPV vaccine recommendations to include a 2-dose schedule for immunocompetent adolescents initiating the vaccination series before their 15th birthday (2). To estimate adolescent vaccination coverage in the United States, CDC analyzed data from the 2016 National Immunization Survey-Teen (NIS-Teen) for 20,475 adolescents aged 13-17 years.* During 2015-2016, coverage increased for ≥1 dose of Tdap (from 86.4% to 88.0%) and for each HPV vaccine dose (from 56.1% to 60.4% for ≥1 dose). Among adolescents aged 17 years, coverage with ≥2 doses of MenACWY increased from 33.3% to 39.1%. In 2016, 43.4% of adolescents (49.5% of females; 37.5% of males) were up to date with the HPV vaccination series, applying the updated HPV vaccine recommendations retrospectively.† Coverage with ≥1 HPV vaccine dose varied by metropolitan statistical area (MSA) status and was lowest (50.4%) among adolescents living in non-MSA areas and highest (65.9%) among those living in MSA central cities.§ Adolescent vaccination coverage continues to improve overall; however, substantial opportunities exist to further increase HPV-associated cancer prevention.
引用
- Walker TY, Elam-Evans LD, Singleton JA, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2016. MMWR Morb Mortal Wkly Rep. 2017. PMID: 28837546. doi:10.15585/mmwr.mm6633a2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。